Purinergic contribution to circulatory, metabolic, and adrenergic responses to acute hypoxemia in fetal sheep.
This study investigated the effects on femoral vascular resistance, blood glucose and lactate levels, and plasma catecholamine concentrations of fetal treatment with an adenosine receptor antagonist during acute hypoxemia in fetal sheep during late gestation. Under anesthesia, seven fetal sheep were instrumented between 117 and 118 days gestation (term is approximately 145 days) with vascular and amniotic catheters and an ultrasonic probe around a femoral artery. Six days after surgery, all fetuses were randomly subjected to a 3-h experiment consisting of 1 h of normoxia, 1 h of hypoxemia, and 1 h of recovery. This was done during either intravenous infusion of vehicle or the adenosine receptor antagonist [8-(p-sulfophenyl)-theophylline; 8-SPT] dissolved in vehicle. During vehicle infusion, all fetuses responded to hypoxemia with bradycardia, an increase in arterial blood pressure, and femoral vasoconstriction. Increases in blood glucose and lactate concentrations and in plasma epinephrine and norepinephrine concentrations also occurred in all fetuses during hypoxemia. Fetal treatment with 8-SPT markedly attenuated the bradycardic, hypertensive, vasoconstrictor, glycemic, and adrenergic responses to hypoxemia, but it did not affect the increase in blood lactate concentrations during hypoxemia. These data show that adenosine is involved in the mechanisms mediating fetal cardiovascular, metabolic, and adrenergic responses to hypoxemia in fetal sheep. Fetal treatment with 8-SPT mimics the effects of carotid sinus nerve section on fetal cardiovascular function during hypoxemia, suggesting a role for adenosine in mediating fetal cardiovascular chemoreflexes.
Giussani
D A
DA
The Physiological Laboratory, University of Cambridge, Cambridge CB2 3EG, United Kingdom. dag26@cam.ac.uk
Gardner
D S
DS
Cox
D T
DT
Fletcher
A J
AJ
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000097:blood*; D004837:Epinephrine / Q000097:blood; D005260:Female; D005263:Femoral Artery / Q000196:embryology / Q000503:physiopathology; D005312:Fetal Blood / Q000737:chemistry; D005315:Fetal Diseases / Q000503:physiopathology*; D005333:Fetus / Q000098:blood supply*; D005865:Gestational Age; D006340:Heart Rate, Fetal / Q000187:drug effects; D000860:Hypoxia / Q000503:physiopathology*; D019344:Lactic Acid / Q000097:blood; D009638:Norepinephrine / Q000097:blood; D011247:Pregnancy; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000502:physiology*; D012756:Sheep; D013806:Theophylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects
D001786:Blood Glucose; D002395:Catecholamines; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D019344:Lactic Acid; C031433:8-(4-sulfophenyl)theophylline; D013806:Theophylline; D009638:Norepinephrine; D004837:Epinephrine